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Abstract
Background: For patients with a normal coagulation system, who experience serious bleeding,
sound evidence for recombinant activated factor VII (rFVIIa) as an effective haemostatic agent is
only scarcely available so far from controlled clinical trials. In systematic reviews on the clinical use
of rFVIIa, treatment failures were only rarely reported.
Case presentation: We present a 45-year old, Caucasian male with persistent intestinal bleeding
due to enterocolitis associated with cytomegalovirus infection and acute graft-versus-host-disease.
He had received allogeneic peripheral blood stem cell transplantation from an unrelated HLA-
identical donor because of chronic myelogenous leukaemia diagnosed two years earlier. Bleeding
started at day 18 after transplantation with bloody diarrhea, which was treated with multiple
transfusions of fresh frozen plasma, platelet, and red blood cell concentrates, and continued
relentlessly, despite all efforts, including continued transfusions, high-dose prednisolone, broad
antibiotic and antiviral coverage, and tranexamic acid. Recombinant FVIIa was started at boluses of
90–120 µg/kg every 4–8 hours. Despite more than 10 doses, recurrent severe bleeding progressed
to refractory shock, multiorgan failure and death.
Conclusions: Little can be concluded from single case reports of clinical improvement, because
publication bias in favour of positive effects is likely. Our case suggests that rFVIIa is not a panacea,
in particular for severe bleeding after bone-marrow transplantation. As long as rigorous, controlled
studies or comprehensive registries are lacking, conventional interventions remain the standard of
care in non-haemophilic patients with severe bleeding.
Introduction
Recombinant activated factor VII (rFVIIa) is an effective
haemostatic agent in approximately 90% of patients with
hemophilia and inhibiting antibodies, and in other types
of complex coagulation disorders [1,2]. It has also been
used in patients with a normal coagulation system, who
experience serious bleeding. For these other patients,
sound evidence from controlled clinical trials is only
scarcely available so far. According to a recent systematic
review, rFVIIa appears to be relatively safe with a 1–2%
incidence of thrombotic complications based on pub-
lished trials [3]. The main safety outcome in a recent trial
on the use of rFVIIa in cerebral haemorrhage was severe
thromboembolism at 90 days [4]; severe arterial and
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venous thromboembolic adverse events were more than
three times as common in the rFVIIa groups as in the pla-
cebo group (7 percent vs. 2 percent), including seven
myocardial infarctions and nine cerebral infarctions (for a
combined rate of 5 percent). In the placebo group of this
study, no arterial thromboembolic events were observed.
In patients with fulminant hepatic failure, rFVIIa was used
after conventional means for treating the associated coag-
ulopathy had failed [5]; in these patients, rFVIIa corrected
the coagulation defect, but thrombotic complications
occurred in two of the four patients (myocardial ischemia
and portal vein thrombosis). This indicates that the rate of
thrombotic complications depends on disease and patient
selection.
Because of this association with serious adverse effects
and the substantial cost, off-label use of rFVIIa may only
be justified in cases with at least some evidence of benefit
and otherwise untreatable life-threatening bleeding. This
is particularly true for diseases with unknown efficacy of
rFVIIa. In a recent systematic review on the clinical use of
rFVIIa from a total of 124 case series and 176 case reports
[3], treatment failures were only rarely reported. This may
indicate outstanding efficacy of rFVIIa, as an "universal
haemostatic agent". Another likely explanation is publica-
tion bias. Therefore, we would like to report a patient with
life-threatening bleeding that failed to respond to
repeated doses of rFVIIa.
Case
We present a patient with persistent intestinal bleeding
due to enterocolitis associated with cytomegalovirus
infection and acute graft-versus-host-disease (GvHD). The
45-year old, Caucasian male had chronic myelogenous
leukemia (CML) which had been diagnosed 2 years ear-
lier. The CML was in its first chronic phase, it was bcr/abl
PCR positive, and had shown only minimal cytogenetic
response to conventional treatment with high-dose
hydroxycarbamide and interferon alpha. Therefore, he
received allogeneic peripheral blood stem cell transplan-
tation from an unrelated HLA-identical donor after condi-
tioning with busulfan and high-dose cyclophosphamide.
The leukocyte nadir was on day +5. Graft take was appar-
ent on day +9 after transplantation, with total leukocytes
recovering to over 1 G/L. Prophylaxis for GvHD consisted
of ciclosporin A, methotrexate, and a short course of low-
dose rabbit antithymocyte globulin. In spite of these
intensive efforts, acute GvHD of the skin (grade III) devel-
oped on day +8, as shown by skin biopsy. Cytomegalovi-
rus infection was diagnosed on day +21 (pp65 was found
in 13 of 200,000 leukocytes), and treated with ganciclovir
and foscarnet. Acute respiratory failure required respira-
tory support. The patient was intubated and transferred to
the intensive care unit on day +20.
Bleeding started at day +18 after transplantation with
bloody diarrhea, which was treated with multiple transfu-
sions of fresh frozen plasma, platelet, and red blood cell
concentrates. Endoscopy revealed diffuse intestinal
mucosal bleeding, from the stomach to the rectum;
biopsy revealed high-grade acute GvHD. Bloody diarrhea
continued despite all efforts, which included frequent
transfusions of platelet and red blood cell concentrates
(Figure), high-dose prednisolone, broad antibiotic and
antiviral coverage, and daily tranexamic acid.
Fresh frozen plasma had been administered repeatedly
earlier than day +24. After admission to the ICU (day +20)
estimated volume losses were replaced by albumin, crys-
talloids and red blood cell concentrates as long as global
coagulation tests were in the high normal range (Figure).
All routine coagulation tests (prothrombin time, activated
partial thromboplastin time and fibrinogen, were per-
formed at least thrice daily. Fibrinogen never fell below
200 mg/dL (reference > 140), prothrombin time (refer-
ence > 70%, Figure) and aPTT always were in plain nor-
mal range, except in the terminal 24 hours. Therefore, we
considered fibrinogen concentrates not to be useful. We
preferred fresh frozen plasma over prothrombin complex
concentrates to replace losses. Prothrombin complex con-
centrates were not used in our patient. Thrombopenia was
treated by platelet concentrate transfusion; additional
desmopressin was not used.
Renal function remained normal. Pulmonary bilateral
infiltrates and need of mechanical ventilation were
unchanged. Body temperature was fluctuating between
37.0 to 39.2 °Celsius, systolic blood pressure between
100 and 170 mmHg with intermittent vasopressor sup-
port. Heart rate was between 110 and 160 /min.
After a period of apparent overall stability (day +24–27)
profuse anal bleeding with declining hemoglobin and
blood pressure prompted massive red blood cell transfu-
sions (Figure) and use of vasopressors. Blood coagulation
tests remained normal.
rFVIIa was started at day +29 with desperation at the unre-
mitting gastrointestinal bleeding, as compassionate use
(Figure). Boluses of 90–120 µg/kg were given every 4–8
hours. After nine doses, rectal bleeding rate decreased, and
PT somewhat shortened (% increase), albeit always in the
normal range (Figure). rFVIIa was discontinued. Less than
24 hours later, on day +33, massive transrectal bleeding
recurred. Hemoglobin fell to 5 g/dL and hypotension
required a sharp increase of vasopressor doses. Recom-
binant FVIIa was started again. Repeat endoscopy con-
firmed diffuse bleeding from severely lacerated mucosa of
stomach and duodenum.Thrombosis Journal 2006, 4:1 http://www.thrombosisjournal.com/content/4/1/1
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Despite massive transfusions and maximal intensive care,
the patient rapidly progressed to multiorgan failure with
progression of bilateral pulmonary infiltrates ("white
lungs"), anuria, severe acidosis, and vasopressor-refrac-
tory hypotension. The patient died one day after start of
the second rFVIIa treatment series, on day +34 after trans-
plantation.
Discussion
rFVIIa was developed for the treatment of hemorrhagic
episodes in haemophilic patients with inhibitors to fac-
tors VIII and IX. Since its introduction, it has also been
used "off-label" to enhance haemostasis in non-haemo-
philic patients who experience bleeding episodes unre-
sponsive to conventional therapy. Conclusive evidence of
its effectiveness in non-haemophilic conditions from con-
trolled clinical trials is not yet available [6,7]. "Last-ditch"
use of rFVIIa in patients with massive haemorrhage resist-
ant to conventional treatment did not rescue these
patients or significantly alter outcomes in a retrospective
study by Clark et al [8]. None of the published rand-
omized, placebo-controlled, double-blind clinical trials of
rFVIIa in non-haemophilic patients with severe bleeding
found significant differences in clinical outcomes. Pro-
phylactic rFVIIa dosing did neither significantly reduce
the number of blood products transfused after major par-
tial hepatectomy [9], nor did it decease the perioperative
blood loss in reconstruction surgery for traumatic fracture
of pelvis and acetabulum [10]. Furthermore, there was no
significant differences in mortality in patients with cirrho-
sis and upper gastrointestinal bleeding when treated with
rFVIIa or placebo [11]. Results from these prospective ran-
domized placebo-controlled trials on the use of rFVIIa as
an adjunct for prevention and therapy of bleeding in sur-
gery and liver diseases recommended, thus, conventional
intervention for prevention and control of haemorrhage
in non-haemophilic patients and contrast thereby to
other more optimistic studies [3-5].
Severe bleeding refractory to standard support is also
common in patients undergoing bone marrow transplan-
tation. In 2001, Blatt and co-workers reviewed their expe-
rience with rFVIIa in three patients treated for pulmonary
haemorrhage, hemorrhagic cystitis, and gastrointestinal
bleeding [12]. Transient clinical responses in gross hae-
maturia and in pulmonary haemorrhage were noted
within several days of starting rFVIIa, but bleeding in new
sites and renewed bleeding at the initial site prompted dis-
continuation of the drug. From that case series it was con-
cluded that large randomized studies are needed before
definitive off-label use in the setting of bone marrow
transplantation can be recommended. On the other hand,
successful treatment with rFVIIa of two bone marrow
transplant patients with pulmonary haemorrhage and
cyclophosphamide-induced hemorrhagic cystitis was
reported, respectively [13,14]. In the recent, randomised
study of rFVIIa in 100 patients with bone marrow trans-
plant-related bleeding [15], the primary outcome, a bleed-
ing score, was not different between rFVIIa and placebo.
Our case illustrates that rFVIIa is not a panacea for refrac-
tory bleeding, in particular for severe bleeding after bone-
marrow transplantation, and in particular for gastrointes-
tinal bleeding. Bleeding is the extravasation of blood.
Extravasation of blood is the inevitable consequence of
injury to vascularized tissues. The extent and duration of
extravasation depends not only on blood coagulation
(platelet aggregation and fibrin formation), but to an
often underappreciated degree also on the degree of dam-
age to the vessel wall (how big are the holes in the vessel
wall), the pressure gradient between vessel lumen and tis-
sue (i.e. blood pressure), and finally on whether compres-
sion at the site on injury is possible (by the hematoma
itself or by medical intervention). Most gastrointestinal
bleedings occur in individuals with normal blood coagu-
lation, e.g. through arrosion of vessels by ulcers, or by
Mallory-Weiss tears. In the gastrointestinal lumen, diffuse
mucosal, and vascular, damage cannot usually be control-
led by compression. Therefore, the expectation that dif-
fuse mucosal gastrointestinal bleeding may be controlled
by augmenting blood coagulation may be considered
naive in many such patients.
Time Course Figure 1
Time Course. Time course of prothrombin time (PT), hae-
moglobin, and platelet count in relation to treatment with 
rFVIIa and blood components. Arrows symbolize one bolus 
of rFVIIa, bars one unit of fresh frozen plasma (FFP), red 
blood cell (RBC), and platelet concentrates (Plt.conc.), 
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Our patient had normal blood coagulation tests, but nev-
ertheless bleeded recurrently. We feel, that with such
severe diffuse damage to gastrointestinal mucosa and ves-
sels, as in our patient, interventions at improving blood
coagulation are of little benefit. This does not only apply
to rFVIIa, but also on other measures available, such as
factor concentrates, plasma, antifibrinolytics, desmopres-
sion or others. To stop bleeding, it is essential to stop the
process of tissue distruction and of vessel damage.
In our patient, we tried rFVIIa, with growing despair
among the young family and among us carers, and with
some hope based on favorable outcomes with rFVIIa in
published case reports. Without continous endoscopy, it
is difficult to verify any short-term changes of bleeding
rates in gastrointestinal bleeding, due to the intermittent
nature of intestinal emptying. The first course of rFVIIa in
our patient may have led to some improvement, but the
concomitant multiple red blood cell transfusions and
steadily declinig hemoglobin thereafter (Figure) warrant
caution with any such conclusion. The massive recurrent
bleeding only 24 h after the last of nine rFVIIa doses is
enough evidence, at least in our view, to judge the inter-
vention ineffective.
Our patient did not exsanguinate (Figure); the last path to
his death was rapidly progressing multiorgan failure.
Bleeding very likely contributed to the tragic outcome, in
particular the terminal, most severe episode.
Little can be concluded from single case reports of clinical
improvement, because publication bias in favour of posi-
tive effects is likely. As long as rigorous, controlled studies
or comprehensive registries do not prove benefit of new
treatments, conventional interventions remain the stand-
ard of care in non-haemophilic patients with severe bleed-
ing [7].
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